Enteric Empty Capsules Market Size & Growth Forecast 2026–2035, By Segments (Product, Application, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Enteric Empty Capsules Market size was around USD 3.29 Billion in 2025 and is slated to grow at a 6.6% CAGR from 2026 to 2035, reaching USD 6.23 Billion by 2035. The industry revenue for 2026 is assessed at USD 3.48 billion.

• Base Year Value (2025): USD 3.29 Billion
• CAGR (2026-2035): 6.6%
• Forecast Year Value (2035): USD 6.23 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Enteric Empty Capsules Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America accounted for 45.30% of the market in 2025, driven by its established pharmaceutical and nutraceutical manufacturing base, advanced formulation capabilities, and strong use of targeted oral delivery systems.
  • Asia Pacific is expected to expand at a 7.46% CAGR as pharmaceutical and nutraceutical production grows, increasing demand for specialized capsule technologies for domestic and export-oriented formulations.

• Segment Momentum:

  • Gelatin capsules accounted for 59.37% of the market in 2025 due to their manufacturing familiarity, cost-efficient production, proven processing compatibility, and reliable integration into pharmaceutical filling and coating operations.
  • HPMC capsules are expanding rapidly because they support evolving formulation needs with greater material flexibility and non-animal-derived options, making them increasingly attractive for specialized pharmaceutical product development.

• Market Expansion Drivers:

  • Rising demand for pharmaceutical drug delivery systems driving adoption of acid-resistant enteric capsules.
  • Increasing prevalence of gastrointestinal disorders boosting need for targeted intestinal drug release solutions.
  • Advancements in capsule coating technologies improving drug stability and expanding pharmaceutical formulation applications.

• Leading Market Participants:

  Key players in the enteric empty capsules market include Lonza Group AG (Switzerland), Roquette Frères S.A. (France), Suheung Co., Ltd. (South Korea), Farmacapsulas S.A. (Colombia), Nectar Lifesciences Limited (India), Zhejiang Huili Capsules Co., Ltd. (China), Shaoxing Zhongya Capsule Co., Ltd. (China), Chemcaps Limited (India), Natural Capsules Limited (India), ACG Worldwide (India).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 3.29 Billion
  • Projected Market Size: USD 6.23 Billion by 2035
  • Growth Forecasts: 6.6% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Gelatin Capsules (Product) | Antibiotic and Antibacterial Drugs (Application) | Pharmaceutical Manufacturers (End-use)
  • Emerging Opportunity Segment: Hydroxypropyl Methylcellulose (HPMC) Capsules (Product) | Antibiotic and Antibacterial Drugs (Application) | Nutraceutical Manufacturers (End-use)

Market Growth Drivers and Industry Trends

Rising demand for pharmaceutical drug delivery systems driving adoption of acid-resistant enteric capsules

As formulation strategies become more focused on protecting active ingredients and controlling where release occurs, the enteric empty capsules market is seeing stronger uptake from pharmaceutical manufacturers seeking alternatives to conventional oral dosage formats. Acid-resistant enteric capsules help developers avoid premature drug release in the stomach, which is particularly important for compounds that are acid-sensitive, irritating to gastric tissue, or intended to act in the intestine. This is influencing product selection early in formulation design, with capsule-based delivery increasingly favored when companies want to reduce reformulation complexity, improve patient acceptability, and speed development timelines for differentiated oral therapies.

Increasing prevalence of gastrointestinal disorders boosting need for targeted intestinal drug release solutions

The growing burden of gastrointestinal conditions is sharpening demand for dosage forms that release active ingredients beyond the stomach, directly supporting expansion of the enteric empty capsules market. In practice, treatment approaches for intestinal inflammation, enzyme supplementation, microbiome-related therapies, and other GI-focused interventions depend on more precise release behavior to improve local action and limit gastric degradation. That need is shaping procurement and formulation decisions among drug manufacturers, as enteric empty capsules offer a practical platform for targeted intestinal delivery without relying solely on more complex tablet coating processes.

Advancements in capsule coating technologies improving drug stability and expanding pharmaceutical formulation applications

Improvements in coating materials and manufacturing precision are strengthening the technical value proposition of the enteric empty capsules market by making capsule performance more reliable under varied formulation requirements. Better control over acid resistance, dissolution timing, and moisture protection allows developers to work with a broader range of active pharmaceutical ingredients, including those with stability challenges or sensitive release profiles. This is expanding the use of enteric empty capsules beyond niche applications, as pharmaceutical companies gain greater confidence in using them for more complex oral products where consistency, compatibility, and manufacturability directly influence commercialization decisions.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising demand for pharmaceutical drug delivery systems driving adoption of acid-resistant enteric capsules	2.00%	High	North America, Europe	High	Near Term
Increasing prevalence of gastrointestinal disorders boosting need for targeted intestinal drug release solutions	1.80%	High	North America, Asia Pacific	High	Near Term
Advancements in capsule coating technologies improving drug stability and expanding pharmaceutical formulation applications	1.50%	Moderate	Europe, Asia Pacific	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading regional position in 2025, accounting for a 45.30% share of the enteric empty capsules market. This leadership is supported by the region’s well-established pharmaceutical and nutraceutical manufacturing base, where demand for capsule formats with targeted intestinal release is closely tied to product development pipelines and contract manufacturing activity. Market activity is further sustained by strong formulation capabilities, regulatory familiarity with advanced oral dosage forms, and steady use of enteric delivery systems in applications where ingredient protection and delayed release are operationally important.

Asia Pacific is set to expand at a 7.46% CAGR over the forecast period in the enteric empty capsules market, driven by the region’s growing pharmaceutical production footprint and increasing adoption of modern capsule-based delivery formats. Growth is accelerating as manufacturers scale output for both domestic consumption and export, creating stronger demand for specialized capsule solutions that support differentiated formulations. Expanding nutraceutical manufacturing and broader use of oral solid dosage products are also reinforcing uptake, particularly where producers are moving toward higher-value delivery technologies to improve product performance and market appeal.

Key Country Insights

United States

Pharma formulation outsourcing

In the United States, enteric empty capsules demand is strongly tied to pharmaceutical formulation outsourcing and nutraceutical product development, with manufacturers relying on specialized capsule technologies to support delayed-release and targeted delivery systems. Contract manufacturing partnerships drive customization across drug and supplement applications.

Japan

Controlled-release demand focus

In Japan, enteric empty capsules demand is influenced by strong requirements for controlled-release drug delivery systems tailored to an aging population and chronic disease management. Pharmaceutical and nutraceutical developers in Japan prioritize capsule technologies that ensure precise gastrointestinal targeting and improved patient compliance.

South Korea

Nutraceutical capsule growth

In South Korea, enteric empty capsules are increasingly utilized in the nutraceutical and dietary supplement sector, where consumer demand for functional health products drives innovation in capsule design and formulation. Manufacturers focus on enhancing bioavailability and taste-masking capabilities for premium supplement offerings.

Germany

GMP capsule specialization

In Germany, enteric empty capsules are primarily driven by stringent GMP compliance requirements and advanced pharmaceutical manufacturing standards, with manufacturers focusing on high-precision capsule engineering for controlled release formulations. Demand is reinforced by established pharmaceutical production clusters emphasizing quality assurance and regulatory adherence.

France

Pharmaceutical grade customization

In France, enteric empty capsules are shaped by pharmaceutical-grade customization needs within hospital and specialty pharmacy environments, where tailored drug delivery solutions are used to improve therapeutic outcomes. French manufacturers emphasize flexible capsule formulation capabilities aligned with clinical prescription requirements.

Italy

Manufacturing efficiency upgrades

In Italy, enteric empty capsules production is influenced by ongoing manufacturing efficiency upgrades within pharmaceutical facilities, with emphasis on improving process consistency and reducing production variability. Italian manufacturers focus on optimizing capsule filling operations to support cost-effective delivery of enteric-coated formulations across therapeutic segments.

Segment Leadership and Growth Trends

  Product Segment Analysis: Gelatin Capsules (Largest Segment) vs Hydroxypropyl Methylcellulose (HPMC) Capsules (Fastest-Growing Segment)

Gelatin Capsules held the strongest position in the enteric empty capsules market in 2025, accounting for a 59.37% share. Their continued dominance is supported by broad manufacturing familiarity, established processing compatibility, and cost-efficient large-scale production across pharmaceutical applications. In the enteric empty capsules market, these factors help gelatin capsules remain the preferred option where manufacturers prioritize reliable supply, proven performance, and smooth integration into existing filling and coating operations.

Hydroxypropyl Methylcellulose (HPMC) Capsules are emerging as the fastest-growing product segment in the enteric empty capsules market because they align well with evolving formulation requirements that demand greater material flexibility and non-animal-derived capsule options. Their momentum is being encouraged by rising preference for capsule formats that support wider ingredient compatibility and meet changing product development needs more effectively than conventional alternatives. This is allowing HPMC capsules to gain traction faster in the enteric empty capsules market, particularly where manufacturers are adapting portfolios to more specialized delivery and consumer-oriented formulation standards.

Application Segment Analysis: Antibiotic and Antibacterial Drugs (Largest & Fastest-Growing Segment)

By 2025, Antibiotic and Antibacterial Drugs represented the largest application in the enteric empty capsules market with a 48.61% share, while also maintaining the strongest growth momentum. This dual position reflects the practical need for capsule formats that can support drug protection and targeted release characteristics important for these therapies. In the enteric empty capsules market, sustained demand from antibiotic and antibacterial drug manufacturing keeps this application at the forefront, while continued reliance on effective oral delivery formats supports further expansion as producers seek dependable encapsulation solutions for these widely used treatments.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	Gelatin Capsules, Hydroxypropyl Methylcellulose (HPMC) Capsules, Vegetable Capsules	Gelatin Capsules	Hydroxypropyl Methylcellulose (HPMC) Capsules
Application	Antacid and Antiflatulent Preparations, Antibiotic and Antibacterial Drugs, Others	Antibiotic and Antibacterial Drugs	Antibiotic and Antibacterial Drugs
End-use	Pharmaceutical Manufacturers, Nutraceutical Manufacturers, Others	Pharmaceutical Manufacturers	Nutraceutical Manufacturers

Competitive Landscape and Market Positioning

Top players in the enteric empty capsules market:

1. Lonza Group AG (Switzerland)

2. Roquette Frères S.A. (France)

3. Suheung Co. Ltd. (South Korea)

4. Farmacapsulas S.A. (Colombia)

5. Nectar Lifesciences Limited (India)

6. Zhejiang Huili Capsules Co. Ltd. (China)

7. Shaoxing Zhongya Capsule Co. Ltd. (China)

8. Chemcaps Limited (India)

9. Natural Capsules Limited (India)

10. ACG Worldwide (India)

Demand for targeted drug delivery systems is shaping the enteric empty capsules market. Improvements in capsule stability and dissolution control are enhancing pharmaceutical performance. In the enteric empty capsules market, formulation innovation is strengthening delivery precision and patient compatibility.

Industry Development/News

Company Name	Date	Key Development
Lonza Group Ltd.	Jun-24	Lonza Group introduced Capsugel Enprotect in a size 9 format designed to protect acid-sensitive active pharmaceutical ingredients from stomach acid and enable enteric release in the intestine. The solution is primarily targeted at pre-clinical rodent studies, aiming to improve early-stage drug evaluation efficiency and accelerate development timelines in pharmaceutical research workflows.
ACG Worldwide	Dec-23	ACG Worldwide’s capsule manufacturing facility in Pithampur, India was recognized under the World Economic Forum’s Global Lighthouse Network. The recognition highlights the facility’s adoption of advanced manufacturing technologies that significantly enhance operational efficiency and digital transformation in pharmaceutical capsule production.
Evonik	Oct-23	Evonik launched the EUDRACAP functional oral capsule platform, including a size 9h enteric-coated capsule designed for preclinical studies. The solution supports smoother transition from preclinical to first-in-human trials by improving drug stability for acid-sensitive compounds and reducing development risk and complexity for pharmaceutical developers.
ACG	May-25	ACG introduced a personalized capsule machine (PCM) enabling on-demand capsule formulation, expanding its capabilities into personalized drug delivery and nutrition solutions. In collaboration with Art of You, the initiative strengthens ACG’s position in customized capsule manufacturing and next-generation oral dosage innovation.
Lonza	Nov-22	Lonza launched Capsugel Enprotect capsules designed for enteric delivery of acid-sensitive active pharmaceutical ingredients, ensuring release in the intestine rather than the stomach. The development strengthened Lonza’s capsule technology portfolio and supported improved formulation stability in pharmaceutical manufacturing.